NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC
NovaBay Pharmaceuticals (NYSE American: NBY) announces its board has determined an unsolicited offer from Refresh Acquisitions BidCo to acquire the Avenova® brand and related assets is a 'Superior Proposal' compared to their existing agreement with PRN. The Refresh offer includes a purchase price of up to $11.5 million (versus PRN's $9.5 million) and a $2.0 million secured term loan. PRN has until November 4, 2024, to submit a revised proposal. Refresh is affiliated with RVL Pharmaceuticals, which commercializes Upneeq®, making Avenova products complementary to their portfolio.
NovaBay Pharmaceuticals (NYSE American: NBY) annuncia che il suo consiglio di amministrazione ha determinato che un'offerta non richiesta da parte di Refresh Acquisitions BidCo per acquisire il marchio Avenova® e i relativi beni è una 'Proposta Superiore' rispetto al loro attuale accordo con PRN. L'offerta di Refresh include un prezzo di acquisto fino a 11,5 milioni di dollari (contro i 9,5 milioni di dollari di PRN) e un prestito termale garantito di 2,0 milioni di dollari. PRN ha tempo fino al 4 novembre 2024 per presentare una proposta rivista. Refresh è affiliata a RVL Pharmaceuticals, che commercializza Upneeq®, rendendo i prodotti Avenova complementari al loro portafoglio.
NovaBay Pharmaceuticals (NYSE American: NBY) anuncia que su junta ha determinado que una oferta no solicitada de Refresh Acquisitions BidCo para adquirir la marca Avenova® y los activos relacionados es una 'Propuesta Superior' en comparación con su acuerdo existente con PRN. La oferta de Refresh incluye un precio de compra de hasta 11,5 millones de dólares (frente a los 9,5 millones de dólares de PRN) y un préstamo a plazo garantizado de 2 millones de dólares. PRN tiene hasta el 4 de noviembre de 2024 para presentar una propuesta revisada. Refresh está afiliada a RVL Pharmaceuticals, que comercializa Upneeq®, lo que hace que los productos Avenova sean complementarios a su portafolio.
노바베이 제약 (NYSE 아메리카: NBY)는 이사회가 리프레시 인수 비드코의 Avenova® 브랜드 및 관련 자산 인수를 위한 비공식 제안을 PRN과의 기존 계약에 비해 '우수한 제안'으로 판단했다고 발표했습니다. 리프레시의 제안에는 1150만 달러의 구매 가격(PRN의 950만 달러와 비교)과 200만 달러의 보장된 양도 대출이 포함됩니다. PRN은 2024년 11월 4일까지 수정된 제안을 제출할 수 있습니다. 리프레시는 Upneeq®를 상용화하는 RVL Pharmaceuticals와 제휴되어 있어 Avenova 제품이 그들의 포트폴리오에 상호 보완적입니다.
NovaBay Pharmaceuticals (NYSE American: NBY) annonce que son conseil d'administration a déterminé qu'une offre spontanée de Refresh Acquisitions BidCo pour acquérir la marque Avenova® et les actifs connexes est une 'Proposition Supérieure' par rapport à leur accord actuel avec PRN. L'offre de Refresh inclut un prix d'achat pouvant atteindre 11,5 millions de dollars (contre 9,5 millions de dollars de PRN) et un prêt à terme garanti de 2,0 millions de dollars. PRN a jusqu'au 4 novembre 2024 pour soumettre une proposition révisée. Refresh est affiliée à RVL Pharmaceuticals, qui commercialise Upneeq®, rendant ainsi les produits Avenova complémentaires à leur portefeuille.
NovaBay Pharmaceuticals (NYSE American: NBY) gibt bekannt, dass der Vorstand entschieden hat, dass ein unangemessenes Angebot von Refresh Acquisitions BidCo zur Übernahme der Avenova®-Marke und der dazugehörigen Vermögenswerte ein 'überlegenes Angebot' im Vergleich zu ihrem bestehenden Vertrag mit PRN ist. Das Angebot von Refresh umfasst einen Kaufpreis von bis zu 11,5 Millionen US-Dollar (im Vergleich zu 9,5 Millionen US-Dollar von PRN) und ein gesichertes Darlehen über 2,0 Millionen US-Dollar. PRN hat bis zum 4. November 2024 Zeit, ein überarbeitetes Angebot einzureichen. Refresh ist mit RVL Pharmaceuticals verbunden, das Upneeq® vermarktet, was die Avenova-Produkte komplementär zu ihrem Portfolio macht.
- Higher purchase price offer of $11.5M compared to PRN's $9.5M
- Additional $2.0M secured term loan from Refresh
- Strategic fit with RVL Pharmaceuticals' existing eye care portfolio
- Transaction remains subject to stockholder approval
- Purchase price subject to downside net working capital adjustment
- Loan amount of $2.0M will be deducted from final purchase price
Insights
The unsolicited offer from Refresh represents a significant
The board's determination of a "Superior Proposal" triggers important legal mechanisms under the original PRN agreement. PRN now has until November 4, 2024, to match or exceed Refresh's offer. The board is maintaining proper fiduciary duty by keeping their recommendation for the PRN deal while exploring the superior offer. The structured process, including independent financial and legal advisor consultation, demonstrates strong corporate governance. The
Refresh’s unsolicited offer provides for terms that are substantially similar to the contemplated transaction with PRN, except that the Company would receive a purchase price of up to
The Company has notified PRN of the board of directors’ determination and that the Company intends to terminate its asset purchase agreement with PRN unless the Company receives a revised proposal from PRN by 11:59 p.m. Pacific time on November 4, 2024, such that the Company’s board of directors determines that Refresh’s unsolicited offer is no longer a Superior Proposal, in accordance with the process provided in the asset purchase agreement with PRN.
“After careful consideration, our board of directors determined that the unsolicited offer by Refresh represents greater value for our stockholders while also placing Avenova in highly capable commercial hands,” said Justin Hall, NovaBay CEO. “Refresh is an affiliate company of RVL Pharmaceuticals, which is commercializing Upneeq® (oxymetazoline hydrochloride ophthalmic solution),
The Company’s asset purchase agreement with PRN, in accordance with such agreement, remains in full force and effect, and the Company’s board of directors has not withdrawn or modified its recommendation regarding stockholders approving the pending transaction with PRN. The Company’s transaction with PRN remains subject to certain closing conditions, including receiving stockholder approval.
Consistent with its fiduciary duties, the Company’s board of directors conducted a comprehensive evaluation of the Refresh unsolicited offer with assistance from independent financial and legal advisors, before making its determination.
About NovaBay Pharmaceuticals, Inc.
NovaBay's leading product Avenova® Lid & Lash Cleansing Spray is often recommended by eyecare professionals for blepharitis and dry eye disease. Manufactured in the
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements are based upon the Company and its management’s current expectations, assumptions, estimates, projections and beliefs. Such statements include, but are not limited to, statements regarding the contemplated transaction with PRN, the unsolicited offer by Refresh and related matters. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in, or implied by, these forward-looking statements. Other risks relating to NovaBay's business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in the Company's latest Form 10-K, subsequent Forms 10-Q and/or Form 8-K filings with the Securities and Exchange Commission (the “SEC”) and the Special Meeting Proxy Statement (as defined below), especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and the Company disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Additional Information and Where to Find It
In connection with the solicitation of proxies, on October 16, 2024, NovaBay filed a definitive proxy statement with the SEC with respect to the special meeting to be held in connection with the proposed asset sale to PRN and a potential voluntary liquidation and dissolution of the Company (the “Special Meeting Proxy Statement”). Promptly after filing the Special Meeting Proxy Statement with the SEC, NovaBay mailed the Special Meeting Proxy Statement and a proxy card to each stockholder entitled to vote at the special meeting to consider the contemplated asset sale to PRN and potential dissolution. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT NOVABAY HAS FILED OR WILL FILE WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders may obtain, free of charge, the Special Meeting Proxy Statement, any amendments or supplements thereto, and any other relevant documents filed by NovaBay with the SEC in connection with the contemplated asset sale to PRN and potential dissolution at the SEC's website (http://www.sec.gov) or at the Company’s investor relations website https://novabay.com/investors/) or by writing to NovaBay Pharmaceuticals, Inc., Investor Relations, 2000 Powell Street, Suite 1150,
Participants in the Solicitation
NovaBay and its directors and executive officers may be deemed to be participants in the solicitation of proxies from NovaBay's stockholders in connection with the contemplated asset sale to PRN and the potential dissolution. A list of the names of the directors and executive officers of the Company and information regarding their interests in the contemplated asset sale to PRN and the potential dissolution, including their respective ownership of the Company’s common stock and other securities is contained in the Special Meeting Proxy Statement. In addition, information about the Company’s directors and executive officers and their ownership in the Company is set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and filed with the SEC on March 26, 2024, as amended on March 29, 2024 and as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of such filing.
Socialize and Stay Informed on NovaBay’s Progress
Like us on Facebook
Follow us on X
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website
Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com
Avenova.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241029844207/en/
NovaBay Contact
Justin Hall
Chief Executive Officer and General Counsel
510-899-8800
jhall@novabay.com
Investor Contact
Alliance Advisors IR
Jody Cain
310-691-7100
jcain@allianceadvisors.com
Source: NovaBay Pharmaceuticals, Inc.
FAQ
What is the purchase price offered by Refresh for NovaBay's (NBY) Avenova brand?
When is PRN's deadline to submit a revised proposal to NovaBay (NBY)?